Intercure - Asset Resilience Ratio
Intercure (INCR) has an Asset Resilience Ratio of 0.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Intercure short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Intercure's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Intercure's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Intercure's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore INCR strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA209.00K | 0.03% |
| Total Liquid Assets | ILA209.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Intercure maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Intercure Industry Peers by Asset Resilience Ratio
Compare Intercure's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Piramal Pharma Limited
NSE:PPLPHARMA |
Drug Manufacturers - Specialty & Generic | 0.73% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Intercure (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Intercure.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.03% | ILA209.00K ≈ $560.32 |
ILA690.55 Million ≈ $1.85 Million |
-0.01pp |
| 2024-12-31 | 0.04% | ILA333.00K ≈ $892.76 |
ILA762.57 Million ≈ $2.04 Million |
+0.02pp |
| 2023-12-31 | 0.02% | ILA187.00K ≈ $501.34 |
ILA786.61 Million ≈ $2.11 Million |
+0.00pp |
| 2022-12-31 | 0.02% | ILA205.00K ≈ $549.60 |
ILA958.01 Million ≈ $2.57 Million |
-0.03pp |
| 2021-12-31 | 0.05% | ILA330.00K ≈ $884.72 |
ILA686.32 Million ≈ $1.84 Million |
-0.07pp |
| 2020-12-31 | 0.12% | ILA376.00K ≈ $1.01K |
ILA326.27 Million ≈ $874.72K |
+0.05pp |
| 2019-12-31 | 0.06% | ILA177.00K ≈ $474.53 |
ILA282.23 Million ≈ $756.66K |
-0.62pp |
| 2018-12-31 | 0.68% | ILA246.00K ≈ $659.52 |
ILA35.92 Million ≈ $96.30K |
-0.65pp |
| 2017-12-31 | 1.34% | ILA319.75K ≈ $857.25 |
ILA23.95 Million ≈ $64.20K |
-0.27pp |
| 2016-12-31 | 1.61% | ILA446.20K ≈ $1.20K |
ILA27.73 Million ≈ $74.35K |
-7.36pp |
| 2015-12-31 | 8.97% | ILA1.13 Million ≈ $3.04K |
ILA12.62 Million ≈ $33.84K |
-54.16pp |
| 2014-12-31 | 63.13% | ILA1.67 Million ≈ $4.47K |
ILA2.64 Million ≈ $7.08K |
+12.34pp |
| 2013-12-31 | 50.79% | ILA3.13 Million ≈ $8.39K |
ILA6.16 Million ≈ $16.53K |
-10.82pp |
| 2012-12-31 | 61.61% | ILA8.95 Million ≈ $24.00K |
ILA14.53 Million ≈ $38.95K |
+61.30pp |
| 2011-12-31 | 0.31% | ILA9.00K ≈ $24.13 |
ILA2.92 Million ≈ $7.83K |
-7.28pp |
| 2010-12-31 | 7.59% | ILA100.00K ≈ $268.10 |
ILA1.32 Million ≈ $3.53K |
-- |
About Intercure
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in… Read more